Clinical-stage radiopharmaceutical company ARTBIO has completed a substantial $132 million Series B financing round to advance its pipeline of alpha radioligand therapies, expand manufacturing capabilities, and support Phase II development of lead candidate AB001 for metastatic castration-resistant prostate cancer.

Cambridge-based ARTBIO has successfully closed a significant financing round that positions the company to accelerate development of its innovative alpha radio-ligand therapies (ARTs) targeting multiple cancer types. The Series B round was co-led by new investors Sofinnova Investments and B Capital, alongside an existing life sciences investment fund, with continued backing from established investors including F-Prime, Omega Funds, and Third Rock Ventures. The funding package also attracted new strategic investors, notably Qatar Investment Authority and Alexandria Venture Investments, reflecting growing confidence in the radiopharmaceutical sector’s therapeutic potential.

Strategic deployment of capital resources

The substantial investment will primarily support advancement of ARTBIO’s lead programme, AB001, through Phase II clinical development for metastatic castration-resistant prostate cancer, currently in first-in-human trials. Additionally, the funding enables progression of undisclosed pipeline programmes toward investigational new drug (IND) readiness whilst expanding the company’s unique manufacturing and supply chain infrastructure.

“This sizable investment from both existing and new investors will enable ARTBIO to continue innovating therapies that treat a range of deadly cancers with power and precision,” said Emanuele Ostuni, Chief Executive Officer of ARTBIO.

The company’s approach centres on harnessing lead-212 (²¹²Pb), an alpha-emitting radioisotope, through precision targeting mechanisms designed to deliver therapeutic payloads directly to tumour sites whilst minimising systemic toxicity.

Emanuele Ostuni,
Chief Executive Officer of ARTBIO

Proprietary technology platform addresses supply challenges

Central to ARTBIO’s commercial strategy is its patented AlphaDirect™ isotope isolation technology, which enables flexible, clinical-grade production of lead-212 with daily therapeutic dose availability. This technological innovation addresses persistent supply chain vulnerabilities that have historically limited radiopharmaceutical development and commercialisation.

“ARTBIO’s approach to ART has the potential to positively change standards of care in cancer,” noted Robert Mittendorff, General Partner at B Capital. “ARTBIO’s lead asset, AB001, is designed to fully harness the unique power of lead-212.”

The distributed manufacturing network strategy aims to improve global access whilst mitigating supply chain risks associated with radioisotope production and distribution.

Scientific foundation and clinical trajectory

ARTBIO’s scientific foundation draws upon nearly a century of radiation therapy research conducted at the University of Oslo and Norway’s Radium Hospital. The company’s integrated approach combines optimal alpha-precursor isotope selection with tumour-specific targeting to create thera­peutics designed for enhanced efficacy and safety profiles.

“With a differentiated ART portfolio and integrated manufacturing approach, ARTBIO represents the ideal company that we look to partner with,” said Maha Katabi, General Partner at Sofinnova Investments.

For more information, visit: www.artbio.com